TP53 and non-small cell lung carcinoma: As knowledge about the carcinogenesis process increases, treatment strategies are becoming more directed, for example, strategies targeting oncogenes that are overexpressed in NSCLC, such as Ras, Myc, Bcl2 and EGFR; or inactivated tumor suppressor genes like Rb and TP53, i.e. strategies that involve inhibiting oncogenes or reactivating tumor suppressor genes3.